ClinicalTrials.gg
RecruitingNCT07272902Updated Oct 20, 2026

Treating Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: Ablation or Medication

An interventional study of Catheter Ablation for Atrial Fibrillation and Rate Control Medications (beta-blockers, calcium channel blockers, digoxin) in Atrial Fibrillation (AF), Heart Failure With Mildly Reduced Ejection Fraction and Heart Failure With Preserved Ejection Fraction (HFPEF), sponsored by Nova Scotia Health Authority. Recruiting at 4 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Nova Scotia Health Authority · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.
Updated Oct 20, 20263 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 318 studies in Atrial Fibrillation with a site in Canada — 50 open to participants now, 73 under way, 8 of them phase 3. Atrial Fibrillation · Canada.

Planned enrollment
199th of 261
84 · median 282
Started
2026
with 9 others
No phase
135 of 318
28 open now
Primary completion
2027-10
later than 42 of 72 live
Registered
312th of 318
by date

Among the 318 studies in Atrial Fibrillation with a site in Canada, this one is the 199th largest by planned enrollment of the 261 interventional ones that give a count, is one of 10 that started in 2026, is one of 135 with no phase, reaches primary completion later than 42 of the 72 other live ones, and was the 312th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

50 of the 318 studies in Atrial Fibrillation with a site in Canada are open now. Recruiting first, the newest first:

44 more — sign in →

All 50 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 318 studies in Atrial Fibrillation with a site in Canada, or all of them as a file.
02

Study summary

This study is testing two different ways of treating atrial fibrillation (AF) in people who also have heart failure with mildly reduced or preserved heart function. Patients will randomly be assigned to either rhythm control using catheter ablation or rate control using medicines. The pilot phase will determine if a larger study can be successfully carried out to see which approach better improves survival, reduces hospitalizations, and enhances quality of life.

03

Conditions studied

  • Atrial Fibrillation (AF)
  • Heart Failure With Mildly Reduced Ejection Fraction
  • Heart Failure With Preserved Ejection Fraction (HFPEF)
  • Rate Control
  • Rhythm Control

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years
  • Diagnosis of atrial fibrillation (documented on Holter, rhythm strip, or )
  • (NYHA) class II-III heart failure
  • (LVEF) >40%
  • Meet specific NT-proBNP criteria:
  • If HF hospitalization within 6 months prior to screening: NT-proBNP >200 pg/ml (if not in AF at screening) or >600 pg/ml (if in AF at screening)
  • Otherwise: NT-proBNP >300 pg/ml (if not in AF at screening) or >900 pg/ml (if in AF at screening)
  • On stable guideline-directed medical therapy for ≥1 month
  • On stable diuretic dose for ≥2 weeks
  • Suitable for either ablation-based rhythm control or rate control strategy

Exclusion criteria

Exclusion Criteria:

  • Permanent atrial fibrillation diagnosis
  • Prior catheter ablation for atrial fibrillation
  • class IV heart failure
  • Rheumatic heart disease
  • Moderate or severe mitral stenosis
  • Mechanical mitral valve
  • Severe aortic stenosis or severe aortic/mitral regurgitation
  • Renal failure requiring dialysis
  • to oral anticoagulation
  • Infiltrative cardiomyopathies
  • Complex congenital heart disease
  • Untreated thyroid disease
  • Acute coronary syndrome or coronary artery bypass surgery within 12 weeks
  • Participation in another clinical trial
  • Inability to provide
  • Other serious non-cardiovascular condition with ≤1 year
  • Age \<18 years
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
84 participants (estimated)

Study arms

  • Active comparator
    Catheter Ablation (Rhythm Control Group)

    Participants in this group will undergo catheter ablation procedure, scheduled within 4 weeks of joining the study.

    Procedure: Catheter Ablation for Atrial Fibrillation

  • Active comparator
    Medical Therapy (Rate Control Group)

    Participants in this group will take medications, with the dosages adjusted over the first few weeks to find the correct dosage.

    Drug: Rate Control Medications (beta-blockers, calcium channel blockers, digoxin)

Interventions

  • ProcedureCatheter Ablation for Atrial Fibrillation

    Participants randomized to this arm will undergo catheter ablation within 4 weeks of randomization. Pulmonary vein isolation is required; additional ablation strategies may be applied at investigator discretion. Guideline-directed medical therapy for atrial fibrillation and heart failure will also be provided.

  • DrugRate Control Medications (beta-blockers, calcium channel blockers, digoxin)

    Participants randomized to this arm will receive pharmacologic therapy to achieve guideline-recommended heart rate control (resting HR \<80 bpm, \<110 bpm with exercise). Therapy may include beta-blockers, non-dihydropyridine calcium channel blockers, or digoxin. If adequate control is not achieved with medication, AV nodal ablation and pacing may be used. Guideline-directed medical therapy for atrial fibrillation and heart failure will also be provided.

06

What researchers measure

Primary outcomes

  1. Feasibility of Trial Conduct

    Recruitment rate (patients recruited per center per month) and crossover rate (percentage of participants switching study arms). Feasibility will be defined as ≥0.7 patients enrolled per center per month and ≤10% crossover.

    Time frame: 12 months after randomization

Secondary outcomes

  1. Composite of Cardiovascular Mortality and Heart Failure Hospitalization

    Time to first event of cardiovascular death (due to MI, sudden cardiac death, HF, stroke, CV procedures, CV bleeding, or other CV cause) or hospitalization for heart failure (admission \>24h, ED visit, or unscheduled IV diuretic administration).

    Time frame: Up to 12 months post-randomization

  2. All-Cause Mortality

    Death from any cause

    Time frame: Up to 12 months

  3. Cardiovascular Hospitalizations and ED Visits (Non-HF)

    Number of hospitalizations or emergency department visits for other cardiovascular causes, including atrial fibrillation.

    Time frame: Up to 12 months

  4. Quality of Life: EQ-5D (Euroquol 5D Questionnaire)

    EQ5D Will include responses from the Euroquol 5D questionnaire

    Time frame: Baseline, 12 months

  5. Quality of Life: AFEQT (Atrial Fibrillation Effect on Quality of Life) Questionnaire

    AFEQT- Atrial Fibrillation Effect on Quality of Life Questionnaire (Scored 0-100, 0 is complete disability, 100 is no disability)

    Time frame: Baseline, 12 months

  6. Quality of life- KCCQ-12 (Kansas City Cardiomyopathy Questionnaire-12)

    KCCQ-12- Kansas City Cardiomyopathy Questionnaire-12 (0-100, 0 is very poor, 100 is excellent)

    Time frame: Baseline, 12 months

  7. Atrial Fibrillation Burden

    Proportion of time in atrial fibrillation as measured by Holter monitoring and symptom-triggered ECG recordings

    Time frame: Baseline, 3, 6, and 12 months

  8. Change in NT-proBNP levels

    Change in plasma NT-proBNP levels from baseline to follow-up

    Time frame: Baseline, 12 months

  9. Change in Left Ventricular Ejection Fraction (LVEF)

    Change in LVEF as measured by echocardiography

    Time frame: Baseline, 12 months

  10. Exercise Capacity (6-Minute Walk Distance)

    Change in distance walked in 6 minutes from baseline to follow-up

    Time frame: Baseline, 12 months

  11. Recruitment Metrics

    Recruitment ration of male vs. female participants, refusal rates and reasons.

    Time frame: Throughout 12-month recruitment

Other outcomes

  1. Procedural Complications

    Symptomatic pulmonary vein stenosis, atrio-esophageal fistula, pericardial effusion requiring pericardiocentesis, major bleeding requiring transfusion.

    Time frame: Up to 30 days post-ablation procedure

  2. Antiarrhythmic Drug Adverse Events

    Incidence of drug-related toxicities (e.g., thyroid, hepatic, pulmonary, proarrhythmia)

    Time frame: Up to 12 months

  3. All-Cause Death

    Number of deaths from any cause

    Time frame: Up to 12 months

07

Study locations

4 of 4 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Oct 2027, 21 months after the start.

Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 21 months is below that.

Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 24, 2025
First posted
Dec 9, 2025
StartActual
Jan 1, 2026
Primary completionEst.
Oct 2027
CompletionEst.
Oct 2027
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites added
Show 3 added (3 Canada)
  • Hamilton Health Sciences · Hamilton, Canada
  • London Health Sciences Centre · London, Canada
  • Montreal Heart Institute · Montreal, Canada
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    3 sites added
    Show 3 added (3 Canada)
    • Hamilton Health Sciences · Hamilton, Canada
    • London Health Sciences Centre · London, Canada
    • Montreal Heart Institute · Montreal, Canada
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07272902
Collaborators
Heart and Stroke Foundation of Canada
Responsible party
Ratika Parkash (Principal Investigator, Nova Scotia Health Authority) — Principal investigator
First posted
Dec 9, 2025
Start date
Jan 1, 2026
Primary completion
Oct 2027 (estimated)
Completion
Oct 2027 (estimated)
Last update
Oct 20, 2026

Study contacts

Laura Hamilton, BSC, MAHSR
Contact
laura.hamilton@nshealth.ca
902-473-7226
Katie Kawulka, BScN, RN
Contact
katie.kawulka@nshealth.ca
902-473-7684

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion